cgp-39393 and Renal-Insufficiency

cgp-39393 has been researched along with Renal-Insufficiency* in 3 studies

Reviews

1 review(s) available for cgp-39393 and Renal-Insufficiency

ArticleYear
Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis.
    Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:9

    Direct thrombin inhibitors (DTIs) are an emerging class of anticoagulants in routine clinical practice, although they have been under investigation for quite some time. Desirudin (Iprivask®, Canyon Pharmaceuticals™) is a recombinant hirudin derivative that directly inhibits free and fibrin-bound thrombin. Desirudin was the first DTI approved for deep vein thrombosis (DVT) prophylaxis in Europe (Revasc®) and is the newest injectable DTI commercially available in the USA. Desirudin is one of the few nonheparin subcutaneous drugs that has demonstrable efficacy for DVT prophylaxis. Subcutaneous desirudin has been shown to be more effective than both subcutaneous unfractionated heparin and enoxaparin, with comparable bleeding rates in the prevention of DVT in patients undergoing elective hip replacement. Desirudin also offers the advantage of a fixed dosing regimen while being less immunogenic than unfractionated heparin. However, owing to its pharmacokinetic properties, patients with renal dysfunction require dosing modifications. The favorable profile shown with desirudin thus far will allow its clinical use to grow and will promote further investigation into broadening its clinical applications.

    Topics: Animals; Anticoagulants; Antithrombins; Dose-Response Relationship, Drug; Hemorrhage; Hirudins; Humans; Recombinant Proteins; Renal Insufficiency; Venous Thrombosis

2011

Trials

1 trial(s) available for cgp-39393 and Renal-Insufficiency

ArticleYear
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
    Clinical pharmacology and therapeutics, 1997, Volume: 62, Issue:1

    To investigate the pharmacokinetics and pharmacodynamics of desirudin in subjects with various degrees of renal impairment in comparison with subjects with normal renal function.. Eight subjects with normal renal function (creatinine clearance > 90 ml/min) received 0.5 mg/kg desirudin intravenously over 30 minutes. Four subjects with mild renal failure (creatinine clearance between 61 and 90 ml/min) received 0.5 mg/kg. Five subjects with moderate renal failure (creatinine clearance between 31 and 60 ml/min) received 0.25 mg/kg. Six subjects with severe renal failure (creatinine clearance < 31 ml/min) received 0.125 mg/kg.. Specific maximum concentration values (maximum concentrations corrected to a dose of 1 mg/kg) increased slightly with decreasing creatinine clearance. Mean specific area under the plasma concentration-time curve increased by a factor of 1.15, 2.83, and 7.0 for subjects with mild, moderate, and severe renal failure, respectively, compared with healthy subjects. Total urinary excretion of desirudin was about 55% to 60% of the dose in all four groups; elimination was delayed for subjects with moderate and severe renal failure. Total and renal clearance of desirudin were proportional to creatinine clearance. Total plasma clearance of desirudin was proportional to renal clearance of the drug. Prolongation of activated partial thromboplastin time was increased among subjects with moderate and severe renal failure despite a dose reduction. Area under the dynamic activated partial thromboplastin time curve for subjects with moderate renal failure remained the same as that for healthy subjects despite a dose reduction by a factor of two. Area under the dynamic curve increased by a factor of about 1.5 for subjects with severe renal failure despite a dose reduction by a factor of four.. A dose reduction by a factor of six is recommended for persons with severe renal failure.

    Topics: Adult; Aged; Anticoagulants; Creatinine; Female; Hirudins; Humans; Male; Middle Aged; Recombinant Proteins; Renal Insufficiency; Severity of Illness Index

1997

Other Studies

1 other study(ies) available for cgp-39393 and Renal-Insufficiency

ArticleYear
Desirudin dosing and monitoring in moderate renal impairment.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:6

    Desirudin is a renally eliminated direct thrombin inhibitor approved to prevent venous thromboembolism. Empiric dosage adjustment and activated partial thromboplastin time (aPTT) monitoring in patients with moderate renal impairment are recommended, but supportive data are lacking. The objective of this study was to evaluate appropriate desirudin dosing in moderate renal impairment and the effect of desirudin on aPTT in moderate renal impairment. Desirudin plasma concentration and aPTT data were extracted from 6 studies. Participants with normal renal function or moderate renal impairment (creatinine clearance [ClCr] 31-60 mL/min) were included. Pharmacokinetic and Monte Carlo simulations were done. After administration of desirudin 15 mg every 12 hours subcutaneously (SC) to steady state, peak desirudin concentrations were 35 and 47 nmol/L in the normal and moderate renal function groups, respectively. Monte Carlo simulations found median 2-hour C(max) concentrations of 51.7 nmol/L in normal renal function and 52.4 nmol/L in moderate renal impairment. Desirudin exhibits a linear relationship when the square root of desirudin concentration is plotted versus the aPTT ratio (r(2) = 0.76). These analyses support the dosing of desirudin at 15 mg every 12 hours SC without aPTT monitoring in patients with moderate renal impairment.

    Topics: Anticoagulants; Drug Administration Schedule; Drug Monitoring; Hirudins; Humans; Injections, Subcutaneous; Monte Carlo Method; Partial Thromboplastin Time; Recombinant Proteins; Renal Insufficiency

2010